ADC Development Services Targeting MUC1

Antibody-drug conjugate (ADC) emerges as an effective and promising agent for targeted cancer therapy. To date, several ADCs have been approved and commercially available in the world. Besides, hundreds of ADCs are investigated actively from early discovery to clinical phase III trials, from hematologic malignancies to solid tumor indications.

Creative Biolabs provides a wide variety of ADC development and manufacturing services against various targets such as the MUC1. With a highly experienced team and world-class facilities, our comprehensive solution to the production of ADCs ranging from construction to characterization. Creative Biolabs’ services are customized to accelerate the development of each ADC according to customers’ requirements.

Introduction of MUC1

MUC1, also known as CD227, is a membrane tethered glycoprotein encoded by the MUC1 gene. It is a single pass type I transmembrane protein, which has a highly glycosylated extracellular domain. Normally, MUC1 is expressed in the glandular or luminal epithelial cells of the mammary gland, stomach, uterus, lungs, pancreas and other organs. MUC1 plays an important role in the protection of the underlying epithelia via extended negatively charged sugar branches to form a physical barrier and inhibit pathogenic colonization. However, abnormal overexpression of MUC1 in human epithelial can cause a variety of cancer diseases such as the ovarian cancer. Thus, it is considered as a biomarker in cancers diagnosis and treatment.

Fig.1 MUC1 overexpression and loss of polarity in cancer cells. (Nath, 2014)

Anti-MUC1 ADC in Ovarian Cancer

MUC1 is highly expressed in ovarian cancer and is regarded as a useful target in ADC-based therapy. For example, CMB-401 is an ADC targeting the MUC1, which is composed of an anti-MUC1 engineered IgG4 antibody linked to a potent cytotoxic antibiotic, calicheamicin through a hydrazone linker. Preclinical studies demonstrated that CMB-401 has significant antitumor activity in vitro and in vivo against ovarian carcinoma. In addition, this ADC presented an acceptable toxicity profile against epithelial ovarian cancer (EOC) in phase I trial. Currently, CMB-401 has been assessed in a phase II trial in patients with ovarian cancer.

Fig.2 Proposed schematic of mechanism of action for ADCs. (Fu, 2018)

What Can We Do for You?

Creative Biolabs has focused on ADCs design and development for years, we are committed to providing customers with high-quality services. We have constructed a variety of mature technology platforms for effective ADC preparation and characterization, including ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis. We will work closely with you to bring satisfied ADCs development services for your drug discovery and research. For further information about our ADCs related products and services, please contact us right now.

References

1. Nath, S.; Mukherjee, P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in molecular medicine. 2014, 20(6): 332-342.
2. Fu, Y.; Ho, M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody therapeutics. 2018, 1(2): 43-53.

For Research Use Only. NOT FOR CLINICAL USE.